The results revealed disturbances in the expression of both genes in the NAFLD group including an increase in SREBP-1-c expression and a decrease in PPAR-α expression, which was previously observed by Wang et al. (2022). The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.